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Abstract. High-risk human papilloma virus (HPV) is 
the leading cause of cervical cancer. HPV oncogenes are 
responsible for the development of malignancy, and the E6 
oncoprotein that HPV expresses induces the degradation of 
tumour suppressor protein p53 (p53). This degradation leads 
to the upregulation of p16; however, unidentified proteins may 
also serve a role in the development and progression of cervical 
cancer. Therefore, the aim of the present study was to analyse 
the expression levels of E6, p53, p16, MDM2 proto-oncogene 
(MDM2) and galectin-3 (gal-3) in cervical cancer specimens. 
A total of 250 cervical cancer tissue slides were used. The 
expression of E6, p53, p16, MDM2 and gal-3 was analysed 
with immunohistochemical methods and a semi-quantitative 
scoring. SPSS software was used for the statistical evaluation of 
staining results and survival analysis of patients with cervical 
cancer. Cervical cancer specimens demonstrated significantly 
increased E6 staining with advanced T-status and increased 
International Federation of Gynecology and Obstetrics clas-
sification. E6, p53 and p16 demonstrated significantly different 
expression levels in squamous epithelial tissue compared with 
adenocarcinomas. MDM2 and gal-3 demonstrated positively 
correlated expression levels in cervical cancer. In addition, gal-3 
expression was correlated with poor prognosis in p16-negative 
cases. A negative correlation between the expression of E6 and 
a mutated form of p53 was also identified in cervical cancer. 
p53 mutation was demonstrated to be common in cervical 
cancer, and gal-3 and MDM2 appeared to act in a combined 
manner in this type of tumour. As gal-3 is overexpressed in 
the cervical cancer tissue of patients with poor prognosis, the 
use of gal-3 inhibitors should be investigated in future studies.
Introduction
Cervical cancer is the fourth most frequent cancer in women 
globally with ~530,000 new cases in 2012, accounting for 
7.5% of all female cancer-associated mortalities (1). A major 
cause of cervical cancer is persistent infection with high-risk 
human papillomavirus (HR-HPV) (1). HPV subtypes 16 and 
18 cause ~70% of all cases of HPV (1,2). At present, >170 HPV 
types have been identified (3). Infection with 15 subtypes of 
HPV (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82) 
may lead to cancer, which is why these 15 types are known 
as carcinogenic or high-risk types (4). The genome of human 
papillomaviruses consists of ~8,000 base pairs and contains six 
early genes (E6, E7, E1, E2, E4 and E5) and two late genes (L1 
and L2) (5). Upon replication of the viral gene E6, E6 oncopro-
tein is expressed, which alters the cell cycle (6). E6 oncoprotein 
and E6-associated protein (E6-AP) form a complex that binds 
to p53 and causes its proteolytic degradation (7).
The tumour suppressor protein p53 (p53) signalling path-
ways leads to cell cycle arrest or apoptosis in case of DNA 
damage (8). As E6 oncoprotein induces the degradation of p53, 
the function of this important cell cycle protein is disturbed 
following HPV infection (9). In addition, the cell cycle regula-
tion protein p16 is expressed at high levels in HPV-infected 
epithelial cells, and thus acts as a marker for the diagnosis 
of HPV-associated carcinoma (9,10). In non-carcinoma 
tissues p53 is regulated by MDM2 proto-oncogene (MDM2) 
through a negative feedback mechanism. MDM2 promotes 
the ubiquitination and proteasome-dependent degradation of 
p53 (11). There is also an association between MDM2, p53 
polymorphism and the progression of cervical carcinoma (12).
A protein previously demonstrated to be associated with 
cervical cancer is galectin‑3 (gal‑3) (5). Galectins are defined 
as lectins with a galactose-binding ability and a characteristic 
amino-acid sequence (13). Galectin is a name proposed by 
Hirabayashi and Kasai (14) for a family of animal lectins. 
Galectins are typically soluble and metal-independent in 
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their activity (15). They have similar features to cytoplasmic 
proteins, including no disulfide bridges, no sugar chains, no 
signal sequences and, in most cases, their N-terminal amino 
acids are acetylated (16). It is possible to classify galectins 
into the following three types on the basis of their structural 
architecture: Proto, chimera and tandem-repeat types. Gal-3 is 
a chimera-type galectin (17).
Gal-3 may increase the invasiveness of cervical cancer by 
activating vascular endothelial growth factor receptor-3 (5). 
Therefore, the aim of the present study was to systematically 
analyse the expression and interactions of E6, p53, p16, MDM2 
and gal-3 in cervical cancer specimens.
Materials and methods
Ethical approval. The present study was approved by the local 
Ethics Committee of the Ludwig-Maximilians-University of 
Munich (approval no. 259-16; Munich, Germany), and was 
performed in compliance with the guidelines of the Helsinki 
Declaration. Patient data were fully anonymised.
Specimens. Archived formalin-fixed paraffin-embedded 
(FFPE) sections from 250 cases of cervical cancer were used 
in the present study; it was possible to analyse 248 cases as 
there was no tumour tissue present on two sections (Table I). 
Cervical dysplasia [cervical intra-epithelial neoplasia (CIN) 
stage III] (18) and non-dysplastic cervical tissue (3 sections of 
each) was used for the E6 immunohistochemical staining, and 
breast cancer tissue was used for the mutated p53 immunohis-
tochemistry. Specimens were obtained from the Department of 
Obstetrics and Gynecology of Ludwig-Maximilians-University 
of Munich, and were obtained from patients undergoing 
surgery there between 1993 and 2002. Follow-up data were 
received from the Munich Cancer Registry (Munich Tumour 
Centre, Munich, Germany).
Immunohistochemistry. The FFPE sections (3-µm-thick) 
were dewaxed in xylol, endogenous peroxidase was inhib-
ited with 3% methanol/H2O2 and sections were rehydrated 
in a descending ethanol gradient. To stain for mutated p53, 
wild-type p53, E6, gal-3 and MDM2, the slides were pre-treated 
in citrate buffer (100˚C; pH 6.0) for antigen retrieval. 
Following this, non‑specific binding of the primary antibodies 
was blocked, and incubation with the primary antibodies 
followed (Tables II and III). Incubation with the secondary 
antibodies and the following steps of the detection system and 
colour development are illustrated in Tables II and III. For p16 
detection, the specimens were automatically stained using the 
Ventana BenchMark XT Stainer (Ventana Medical Systems, 
Inc., Oro Valley, AZ, USA) and the CINtec Histology kit 
(cat. no. 9517; Roche Applied Science, Mannheim, Germany) 
according to the manufacturer's instructions, while all other 
antibodies were stained for manually. For wild-type p53, the 
slides were washed in PBS/0.05% Tween-20. All other slides 
were washed in PBS only. Finally, the slides were counter-
stained with hemalaun (Waldeck GmbH, Münster, Germany) 
for 2 min at room temperature, dehydrated in an ascending 
series of ethanol and stored.
Slides were examined with a Zeiss Axiophot light photo-
microscope (Zeiss GmbH, Jena, Germany). Digital images 
were obtained with a digital-camera system (CF20DXC; 
KAPPA Messtechnik, Gleichen, Germany). All specimens 
were evaluated by a pathologist. The intensity and distribution 
patterns of the staining reaction was evaluated by two blinded, 
independent observers, including the gynecological patholo-
gist, using the semi-quantitative immunoreactive (IRS)-score, 
as previously described (19), to asses steroid receptors (20) 
and cathepsin D (21) expression. The IRS score was calcu-
lated by multiplication of optical staining intensity (graded 
as 0, no staining; 1, weak staining; 2, moderate staining; and 
3, strong staining) and the percentage of positive stained cells 
(0, no staining; 1, ≤10% of the cells, 2, 11‑50% of the cells, 
3=51‑80% of the cells and 4, ≥81% of the cells) and without 
knowing the pathological evaluation, the diagnosis or the 
standard performed hematoxylin reaction for 2 min at room 
temperature for each specimen.
Statistical analysis. Data were analysed using SPSS soft-
ware (version 19.0; IBM SPSS, Armonk, NY, USA) for 
Microsoft Windows and visualised using Microsoft Office 7 
(Microsoft Corporation, Redmond, WA, USA). Spearman 
coefficients were calculated to assess correlations, while the 
Table I. Clinical parameters of the patients included in the 
present study.
Clinical parameter No./total no. %
Age (years)
  ≤50 143/248 58
  >50 105/248 42
No. of metastasis positive lymph nodes
  0 149/248 60
  1-4 97/248 39
  NA 2/248   1
Tumour size (cm)
  <2 111/248 45
  2-4 128/248 52
  >4 9/248   3
Tumour grade
  I 20/248   8
  II 141/248 57
  III 78/248 31
  NA 9/248   4
Tumour subtype
  Squamous 199/248 80
  Adenocarcinoma 49/248 20
Progression (over 236 months)
  None 190/248 77
  ≥1 58/248 23
Survival (over 236 months)
  Right censured 210/248 85
  Succumbed 38/248 15
NA, not applicable as data not available.
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Mann-Whitney U test was applied to examine differences 
between groups. Differences in survival were assessed using 
the log-rank test and survival curves were plotted in accor-
dance with Kaplan-Meier estimator. P<0.05 was considered 
to indicate a statistically significant difference and data 
were expressed as the mean ± standard error. Cox regression 
analysis was used to compare the risk of mortality in patients 
with and without gal-3 expression when the effects of further 
factors were accounted for. Independent variables included 
in the Cox regression model were gal-3 expression, age at the 
time of surgery, histological subtype, tumour size, lymph node 
status (pN), metastasis, tumour grade, International Federation 
of Gynecology and Obstetrics (FIGO) stage (22,23), and E6, 
mutated p53 and MDM2 expression status.
Results
Evaluation of E6 oncoprotein immunohistochemistry and 
the detection of mutated p53 on control slides. CIN III tissue 
slides were used for the evaluation of E6 oncoprotein staining. 
Moderate expression levels of E6 were observed in the CIN III 
sections (Fig. 1A). There was no expression of the E6 oncopro-
tein, and therefore no staining observed, in the non-dysplastic 
cervical tissue (Fig. 1B). Breast cancer tissue was used to 
evaluate the staining of mutated p53 (Fig. 1C), which exhibited 
nuclear and cytoplasmic staining.
E6 oncoprotein staining. A total of 81% of all cervical 
cancer tissue examined expressed E6 oncoprotein (data not 
shown). Cervical cancer specimens demonstrated significantly 
increased staining with a higher T stage (according to the 
Tumor‑Node‑Metastasis classification system) (24). T1 stage 
carcinomas (Fig. 2A) demonstrated E6 staining with a median 
IRS of 2, while T2 (Fig. 2B) and T3 (Fig. 2C) stage carcinoma 
tissues had a significantly higher median E6 expression of 
IRS 3 (P=0.017; Fig. 2D).
FIGO 1 carcinoma tissues had a median E6 expression 
of IRS 2 (Fig. 2E). FIGO 2 (Fig. 2F) and FIGO 3 (Fig. 2G) 
carcinoma tissues had a median IRS of 4. FIGO 4‑classified 
cervical cancer tissue had a median E6 IRS score of 6 (Fig. 2H). 
E6 demonstrated a significant positive correlation with the 
FIGO classification (R=0.277, P<0.001; Fig. 2I).
Table II. Procedures for gal-3 and MDM2 staining.
Protocol Gal-3 MDM2
Blocking method Horse seruma, 20 min, RT Goat seruma, 20 min, RT
Primary antibody, dilution, Anti-galectin-3, 1:1,000 in PBS,  Anti-MDM2, 1:100 in PBS, 16 h,
incubation duration, incubation 16 h, 4˚C; NCL‑GAL3b 4˚C, NCL‑MDM2b
temperature, cat. no.
Secondary antibody, Biotynilated anti-mouse IgGa, Biotinylated goat anti-mouse IgM, 
dilution, incubation duration, 30 min, RT; PK-6100 30 min, RT ZMB2020c
incubation temperature, cat. no.
Detection of secondary antibody ABC-complexa, 30 min ABC-complexa, 30 min
Chromogen 1 mg/ml DABd, 5 min 1 mg/ml DABd, 1 min
aVectastain ABC kit; Vector Laboratories, Inc., Burlingame, CA, USA. bNovocastra; Leica Microsystems GmbH, Wetzlar, Germany. 
cLinaris GmbH, Dossenheim, Germany. dDako, Glostrup, Denmark. Gal-3, galectin-3; MDM2, MDM2 proto-oncogene; Ig, immunoglobulin; 
DAB, 3,3'-diaminobenzidine; RT, room temperature.
Table III. Procedures for mutated p53, wild-type p53 and E6 staining.
Protocol Mutated p53 p53 wild-type E6
Blocking method Reagent 1a; 5 min, RT Reagent 1a; 5 min, RT Reagent 1a; 5 min, RT
Primary antibody, dilution, Anti-p53, 1:100 in PBS,  Anti-p53, 1:200 in PBS, Anti-E6, 1:150 in PBS,
incubation duration, incubation 16 h, 4˚C, ab32049b 16 h, 4˚C, ab26b 1 h, RT, ab70b
temperature, cat. no.
Post blocking method Reagent 2a; 20 min, RT Reagent 2a; 20 min, RT  Reagent 2a; 20 min, RT
Secondary antibody, dilution, HRP-Polymer Reagent 3a, HRP-Polymer Reagent 3a, HRP-Polymer Reagent 3a; 
incubation duration, incubation 30 min, RT POLHRP-100 30 min, RT POLHRP-100 30 min, RT POLHRP-100
temperature, cat. no.
Chromogen 1 mg/ml DABc, 1 min 1 mg/ml DABc, 1 min 1 mg/ml DABc, 1 min
aFrom the ZytoChem-Plus HRP Polymer-kit; Zytomed Systems GmbH, Berlin, Germany. bAbcam, Cambridge, UK. cDako, Glostrup, Denmark. 
RT, room temperature; HRP, horseradish peroxidase; DAB, 3,3'-diaminobenzidine.
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Figure 2. E6 expression is enhanced with cervical cancer tumour staging. (A) Low intensity E6 expression was observed in T1 tumours, whereas (B) T2 
and (C) T3 staged tumours demonstrated increased expression of E6. (D) Box plot summary of the IRS for each tumour stage (P=0.017, FIGO 1 vs. 3). E6 
expression was positively correlated with FIGO classification, with (E) FIGO 1 classified tissue demonstrating low expression of E6 while (F) FIGO 2 and 
(G) FIGO 3 classified tissue demonstrated increased expression levels, and (H) FIGO 4 tissue further increased expression levels. (I) Box plot summary of the 
IRS for each FIGO stage (P<0.001, FIGO 1 vs. 4). (J) Squamous epithelial tissue demonstrated lower levels of E6 staining than (K) adenocarcinoma tissue. 
(L) Box plot summary of the IRS for each histological subtype. Scale bar, 200 µm. FIGO, International Federation of Gynecology and Obstetrics; IRS, immu-
noreactive score; E6Cyt, E6 cytoplasmic; pT, pathological tumour stage.
Figure 1. Representative images of the staining for E6 in dysplastic and non-dysplastic cervical tissue samples, and mutated tumour protein p53 in breast cancer 
samples. (A) E6 staining in cervical dysplasia. (B) No expression of E6 was detected in non-dysplastic cervix samples. (C) Breast cancer tissue demonstrated 
expression of mutated p53. Scale bar, 200 µm.
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E6 demonstrated significantly different expression levels 
in cervical cancer tissue dependent on the histological 
subtype. Squamous epithelial carcinomas (Fig. 2J) had a 
median expression of IRS 2. Adenocarcinoma tissue (Fig. 2K) 
had significantly increased staining with a median of IRS 5 
(P=0.015 vs. squamous epithelial carcinoma; Fig. 2L).
Wild‑type and mutated p53 expression. Expression of 
wild-type p53 was observed in the nucleus and cytoplasm of 
60 and 66% of all cervical cancer specimens, respectively. 
Significantly different expression levels in cervical cancer 
tissue in different histological subtypes were also observed 
for p53 expression. Wild-type p53 demonstrated a median 
nuclear expression (Fig. 3A) of IRS 1 in squamous epithelial 
tissue, whereas in adenocarcinoma tissue (Fig. 3B) the median 
nuclear expression was significantly decreased in comparison 
(IRS 0, P=0.024; Fig. 3C).
In addition to nuclear expression, wild-type cytosolic p53 
expression also demonstrated significant differences associ-
ated with the histological subtype. In squamous epithelial 
tissue (Fig. 3D) a median expression of IRS 3 was observed, 
whereas in comparison the median cytosolic expression of p53 
was significantly decreased in adenocarcinoma tissue (Fig. 3E) 
to IRS 0 (P<0.001; Fig. 3F).
The monoclonal antibody that recognises a previously 
described mutated form of p53, (25) also revealed significant 
staining differences associated with the histological subtype of 
cervical cancer. In addition, 42% of all cervical cancer tissue 
slides demonstrated nuclear expression of mutated p53, and 
67% of all cases demonstrated mutated p53 expression in the 
cytoplasm. Although the median expression of mutated p53 
in squamous epithelial tissue (Fig. 3G) and adenocarcinoma 
tissue (Fig. 3H) was 0, differences between the subtypes were 
significant (P=0.011; Fig. 3I).
Expression of p16 oncoprotein in cervical cancer tissue. p16 
overexpression is routinely used in the Pathology Department 
of the Ludwig-Maximilians-University of Munich as a 
marker for HPV-associated head and neck squamous carci-
noma (11). A total of 94% of cervical carcinoma cases tested 
Figure 3. Tumour protein p53 expression in cervical cancer tissues. (A) Squamous epithelial tissue demonstrated a nuclear expression of wild-type p53, whereas 
(B) adenocarcinoma tissue had lower levels of p53 nuclear staining. (C) Box plot summary of the nuclear p53 IRS for each histological subtype. (D) Squamous 
epithelial tissue demonstrated higher expression of wild-type p53 in the cytoplasm compared with (E) adenocarcinoma tissue. (F) Box plot of the cyto-
plasmic p53 IRS for each histological subtype. (G) Squamous epithelial tissue demonstrated expression of mutated p53, while (H) adenocarcinoma tissue 
demonstrated almost no staining. (I) Box plot summary of the mutated p53 IRS for each histological subtype. Scale bar, 200 µm. IRS, immunoreactive score; 
p53Cyt, cytoplasmic wild-type p53; p53mut, mutant p53.
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demonstrated p16 expression, and 61% of these cases were 
p16-overexpressing according to pathological evaluation. The 
cell cycle protein p16 demonstrated significant differences in 
expression between different histological subtypes of cervical 
cancer. Squamous epithelial tissue (Fig. 4A) had a median 
expression of IRS 6, while adenocarcinoma tissue (Fig. 4B) 
had a significantly lower expression in comparison, with an 
IRS of 4 (P<0.001; Fig. 4C). Notably, p16 demonstrated no 
significant correlation with E6 oncoprotein expression (data 
not shown).
Correlation analysis. A significant correlation was identified 
between MDM2 and gal-3 expression in cervical cancer tissue 
(R=0.181, P=0.005; data not shown). Cases of cervical cancer 
with low MDM2 expression (Fig. 5A) also demonstrated low 
gal-3 expression (Fig. 5B). Likewise, a case with high MDM2 
expression (Fig. 5C) demonstrated high gal-3 expression 
(Fig. 5D). Cases of cervical cancer with low E6 oncoprotein 
expression (Fig. 5E) demonstrated enhanced staining of the 
mutated form of p53 in the same area of the tumour (Fig. 5F). 
However, cases with high expression of E6 (Fig. 5G) revealed 
low expression of mutated p53 (Fig. 5H). The statistical 
evaluation confirmed these results of serial section staining 
(R=‑0.140, P=0.028; Table IV). A significant correlation was 
also identified between the expression of MDM2 and mutated 
p53 in cervical cancer tissue (R=0.144, P=0.025; Table IV). The 
correlation analyses and clinical parameters are summarised 
in Table IV.
Gal‑3 is a negative prognosticator in p16‑negative patients 
with cervical cancer. In patients with cervical cancer with no or 
very low p16 expression, gal-3 expression was correlated with a 
Figure 5. Expression of MDM2 and gal‑3 in cervical cancer. Low expression of (A) MDM2 and (B) gal‑3 was identified in the same area of cervical cancer. In 
another case, high expression of (C) MDM2 and (D) gal-3 were observed in the same are. Samples with (E) low E6 expression demonstrated high expression 
levels of (F) mutated p53. Another serial slide series with high expression of (G) E6 demonstrated low expression of (H) mutated p53. Scale bar, 200 µm. 
MDM2, MDM2 proto-oncogene; gal-3, galectin-3.
Figure 4. Expression of p16 in cervical cancer tissues (A) Squamous epithelial tissue demonstrated higher p16 expression levels compared with (B) adenocar-
cinoma tissue. (C) Box plot summary of the p16 IRS for each histological subtype. Scale bar, 200 µm. IRS, immunoreactive score; p16Cyt, cytoplasmic p16.
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poor prognosis in overall survival analyses (P=0.0313; Fig. 6). 
Multivariate Cox regression analysis was performed to test 
which histopathological variables were independent prognos-
ticators for survival rate in the tested breast cancer collective. 
It was demonstrated that the histological subtype (P=0.02), 
tumour size (P=0.011) and pN (P=0.045) were independent 
prognosticators for overall survival (Table V). No significant 
effect was demonstrated for the other histopathological vari-
ables.
Discussion
Within the present study, immunohistochemical evaluation 
of E6 oncoprotein expression was conducted. In addition, E6 
expression levels were demonstrated to be associated with the 
histological subtype. The expression of wild-type p53 and a 
mutated form of p53 were identified in the cervical cancer 
specimens tested. Finally, correlation analyses revealed a 
combined positive expression pattern for galectin-3 and 
MDM2, and a negative correlation between E6 and mutated 
p53 expression.
Although the early era of HPV research identified that 
≤99.5% of cervical cancer cases are HPV‑associated (26), 
it remains controversial in the literature whether viral load 
and disease severity are positively correlated (12). Therefore, 
the present study investigated a number of markers that are 
associated with HPV-driven changes in cell cycle proteins. 
Using these markers permitted a comparative analysis of the 
influence of HPV on the progression of cervical cancer for 
>10 years following surgery.
The replication of the viral genes E6 and E7 results in the 
cellular expression of E6 and E7 oncoproteins, which inter-
fere with the cell cycle (6). E6 oncoprotein binds to E6-AP, 
forming a complex that selectively binds to p53 and leads to its 
ubiquitin-dependent proteolytic degradation (7). The present 
study demonstrated that E6 immunohistochemistry was a fast 
and simple method for the detection of the HPV-associated 
oncoprotein E6 in cervical cancer tissues. As a routine 
practice, E6 and E7 are detected using either in situ hybridisa-
tion (11) or polymerase chain reaction (27) methodology due 
to the non‑specific immunohistochemical staining results of 
antibodies used in former studies (28).
In the present study a well‑tested antibody, and specific 
antigen retrieval and staining protocol was used, resulting in 
the establishment of a useful immunohistochemical evaluation 
protocol for the detection of the HPV E6 oncoprotein. The 
optimal results were obtained with the E6 antibody supplied 
by Abcam (Cambridge, UK). The advantage of immuno-
histochemical evaluation is that it is easier to apply and less 
expensive compared with mRNA in situ hybridisation. mRNA 
in situ hybridisation may be the optimal way to detect HPV; 
however, this method is more complicated for routine detec-
tion compared with immunohistochemistry (26). Evaluation 
of E6 immunohistochemical staining in cervical cancer tissue 
has previously revealed positive correlations with advanced 
T staging and FIGO classification (22). Although specific studies 
have indicated correlations between E6/E7 gene expression and 
the clinicopathological parameters of cervical cancer (26), such 
a correlation was not demonstrated in the present study.
An additional finding of the present study is the negative 
correlation between E6 and mutated p53 expression. Mutations 
of the gene encoding p53 (TP53) are the most frequent altera-
tions in multiple human malignancies (29-31). In total, >50% 
of human tumours contain a mutation/deletion of TP53, 
ranging from 5-80% depending on the type, stage and etiology 
of the tumours (32). A number of previous studies have inves-
tigated a potential genetic link between these variations and 
cancer susceptibility, but the results have been controversial. 
A previous meta-analysis study from 49 pooled studies failed 
to demonstrate a link between a common TP53 mutation (25) 
and cervical cancer susceptibility (33). Later on, the same 
mutation was revealed to be associated with higher pancreatic 
cancer risk among males; however, results also indicated that 
it may protect Arab women against the development of breast 
cancer (34,35). Multiple other mutations of TP53 have since 
been described. Mutations that deactivate p53 in cancer are 
primarily located in the central DNA binding domain. These 
mutations typically ablate the ability of the protein to bind to 
Figure 6. Kaplan-Meier overall survival analyses for patients with cervical 
cancer with gal-3 expression (red) compared with those with no gal-3 
expression (black). Gal-3, galectin-3.




Parameters P-value ratio Lower Upper
Age (years) 0.071 1.029 0.997 1.062
Histology 0.002 3.576 1.586 8.063
pT 0.011 1.270 1.057 1.525
pN 0.045 2.113 1.016 4.395
pM 0.702 1.305 0.335 5.085
Tumour grade 0.065 1.717 0.968 3.048
FIGO 0.875 0.994 0.926 1.068
E6CytIRS 0.475 0.961 0.863 1.071
p16CytIRS 0.696 1.026 0.903 1.165
p53IRS 0.267 0.892 0.729 1.092
p53mutIRS 0.975 0.996 0.765 1.296
MDM2IRS 0.460 1.050 0.922 1.196
Gal-3 IRS score 0.452 0.937 0.792 1.109
CI, confidence interval; pT, pathological tumour stage; pN, patho logical 
node stage; pM, pathological metastasis stage; FIGO, International 
Federation of Gynecology and Obstetrics stage; IRS, immunoreactive 
score; Cyt, cytoplasmic; mut, mutated; MDM2, MDM2 proto-onco-
gene; Gal-3, galectin-3.
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its target DNA sequences, prevent the transcriptional activation 
of p53 target genes. In total, ~80% of the most common p53 
mutants demonstrate the capacity to exert dominant-negative 
effects over wild-type p53 and thus prevent the activation 
of transcription. In contrast, only 45% of the less frequent 
mutants studied have this capacity (36).
The mutation detected by the antibody used in the present 
study is an mutation at position 20 (serine to aspartic acid), 
which abolishes the phosphorylation site on p53. The phos-
phorylation of this serine when DNA damage is detected 
weakens the interaction between p53 and MDM2, thereby 
stabilising p53 (37-39). Thus, this mutation maintains increased 
protein levels of p53 following DNA damage. The analysis of 
the immunohistochemical detection of mutated p53 revealed 
that cervical cancer specimens derived from squamous 
epithelial tissue demonstrated significantly higher expression 
levels compared with adenocarcinoma tissue. In addition, a 
positive correlation between the expression of mutated p53 and 
MDM2, and a negative correlation between the expression of 
mutated p53 and E6, were identified. Therefore, it is possible 
to speculate that E6 also degrades the mutated form of p53. In 
a previously published study, this mutation was demonstrated 
to be associated with the improved survival of patients with 
cervical cancer (25).
Finally, a positive correlation between MDM2 and gal-3 
expression was demonstrated in cervical cancer tissue. Little 
information concerning the involvement of galectins in cervical 
cancer exists at present. Research has primarily focused on 
gal-1 (40,41), gal-7 (42,43) and gal-9 (44). A previous publica-
tion described the influence of gal‑3 on vascular endothelial 
growth factor C expression and its influence on the enhance-
ment of cervical cancer cell invasiveness (5). The present study 
demonstrated that gal-3 was a negative independent prognos-
ticator for the overall survival of patients with p16-negative 
cervical cancer. In this group of patients, gal-3 may be respon-
sible for the aggressiveness of cervical cancer, whereas in 
p16-positive carcinomas different factors/signal transduction 
pathways may be responsible.
In the present study, a total of 250 cervical cancer cases 
were systematically analysed for the expression and interac-
tion of E6, p53, p16, MDM2 and gal-3 in FFPE tumour tissue. 
Significantly increased levels of E6 staining were correlated 
with an advanced T stage and FIGO classification. Furthermore, 
MDM2 and gal-3 expression levels were positively correlated 
in cervical cancer. In addition, gal-3 expression levels were 
negatively correlated with prognosis in p16-negative cases. As 
gal-3 is overexpressed in the cervical cancer tissue of patients 
with a worse prognosis, the investigation of gal-3 inhibiting 
compounds is an additional task for the development of alter-
native treatments for this tumour type. In addition, a negative 
correlation between E6 and a mutated form of p53 in cervical 
cancer was identified. In conclusion, the results of the present 
study indicate that immunohistochemical staining may be a 
useful method for the detection the HPV E6 oncoprotein.
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